Directs deal sourcing and operational due diligence across technology and healthcare buyouts, allocating capital into companies undergoing digital transformation and operational scale-ups. Stephen Dodson brings investment committee experience in structuring growth equity and control transactions, alongside portfolio operational roles that drove margin expansion and revenue acceleration. Prior roles span principal-level investing and corporate strategy; education includes an MBA and undergraduate degree in economics. Market relevance centers on deal origination in North America and hands-on portfolio value creation for institutional LPs.
Directs deal sourcing and operational due diligence across technology and healthcare buyouts, allocating capital into companies undergoing digital transformation and operational scale-ups. Stephen Dodson brings investment committee experience in structuring growth equity and control transactions, alongside portfolio operational roles that drove margin expansion and revenue acceleration. Prior roles span principal-level investing and corporate strategy; education includes an MBA and undergraduate degree in economics. Market relevance centers on deal origination in North America and hands-on portfolio value creation for institutional LPs.
Focuses on growth-oriented control and structured growth equity investments in technology and healthcare businesses undergoing digital transformation and operational scale-ups. Prefers North American mid-market companies where active governance, KPIs-driven operational playbooks, and selective add-on M&A accelerate revenue and margin expansion. Capital allocation favors staged commitments tied to operational milestones, with a 3–7 year value-creation horizon and disciplined downside protection via covenants and governance rights. Investment decisions combine thematic sector research, rigorous operational due diligence, and hands-on portfolio interventions to de-risk execution and drive exit optionality.
Focuses on growth-oriented control and structured growth equity investments in technology and healthcare businesses undergoing digital transformation and operational scale-ups. Prefers North American mid-market companies where active governance, KPIs-driven operational playbooks, and selective add-on M&A accelerate revenue and margin expansion. Capital allocation favors staged commitments tied to operational milestones, with a 3–7 year value-creation horizon and disciplined downside protection via covenants and governance rights. Investment decisions combine thematic sector research, rigorous operational due diligence, and hands-on portfolio interventions to de-risk execution and drive exit optionality.
| Trades 28 | Longs Won 14/28 50% | Profit Factor 2.28 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.36M |
| Average Win $1.88M | Best Trade (Jul 19) $10.2M | Sharpe Ratio -18.19 |
| Average Loss -$826,271.62 | Worst Trade (Jul 19) -$2.54M | Z-Score 0.19 (15.27%) |
| Commissions $0 | Avg. Trade Length 1y 5m 4w 1d | Expectancy $527,338.93 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.03% | 0.57% | 8.75% |
| Consecutive Losing Trades | 149 | 134 | 119 | 105 | 90 | 75 | 60 | 45 | 30 | 15 |